{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:12:38Z","timestamp":1791303158055,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,4,6]],"date-time":"2009-04-06T00:00:00Z","timestamp":1238976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\/Aims: <\/jats:bold> Non\u2010alcoholic fatty liver disease and non\u2010alcoholic steatohepatitis (NASH) are the hepatic manifestation of metabolic syndrome. However, its therapeutic strategy has not been established. Recently, an angiotensin II type 1 receptor blocker, telmisartan (Tel), has received a great deal of attention as a therapeutic tool for metabolic syndrome. The aim of this study was to investigate the efficacy and mechanisms of Tel on a murine NASH model.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> C57BL\/6 mice were fed a methionine\u2010 and choline\u2010deficient high\u2010fat diet (MCDHF) or a standard diet with\/without the administration of Tel (10\u2003mg\/kg\/day) for 8 weeks.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> MCDHF feeding induced marked steatohepatitis with macrophage infiltration. Tel attenuated liver steatosis with decreased hepatic triglycerides (P&lt;0.05) and fibrogenesis with decreased type I collagen and transforming growth factor\u2010\u03b21 mRNA expressions (P&lt;0.05). Tel also suppressed the infiltration of macrophages into the liver and decreased hepatic monocyte chemoattractant protein\u20101 and its receptor (CC\u2010chemokine receptor 2; CCR2) mRNA expressions, especially CCR2. <jats:italic>In vitro<\/jats:italic>, Tel suppressed CCR2 expression, which was induced by low\u2010density lipoprotein. The size of adipocyte in visceral fat tissue was reduced with an increased serum adiponectin concentration in the Tel group.<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> In this study, we revealed that Tel attenuated steatohepatitis progression by suppressing the macrophage infiltration into the liver. Tel also affected the reduction of adipocyte size and elevation of serum adiponectin. Tel might serve as a new therapeutic strategy for NASH.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2009.02006.x","type":"journal-article","created":{"date-parts":[[2009,4,6]],"date-time":"2009-04-06T09:42:42Z","timestamp":1239010962000},"page":"988-996","source":"Crossref","is-referenced-by-count":70,"title":["Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue"],"prefix":"10.1111","volume":"29","author":[{"given":"Hiroshi","family":"Kudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakiyo","family":"Sasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,2]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"594","article-title":"Nonalcoholic steatohepatitis","volume":"20","author":"Lee RG.","year":"1989","journal-title":"a study of 49 patients"},{"key":"e_1_2_5_3_2","first-page":"373","article-title":"NASH and insulin resistance","volume":"35","author":"Chitturi S","year":"2002","journal-title":"insulin hypersecretion and specific association with the insuline resistance syndrome"},{"key":"e_1_2_5_4_2","first-page":"74","article-title":"The natural history of nonalcoholic steatohepatitis","volume":"11","author":"Powell EE","year":"1990","journal-title":"a follow-up study of forty-two patients for up to 21 years"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.28231"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1999.277.5.E920"},{"key":"e_1_2_5_7_2","first-page":"507","article-title":"PPAR\u2010gamma","volume":"47","author":"Spiegelman BM.","year":"1998","journal-title":"adipogenic regulator and thiazolidinedione receptor"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20420"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000123072.34629.57"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.12.3442"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.12.1983"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm788"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200422422"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317797"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.08.029"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.9.2094"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.02279-06"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature02583"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200319246"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000126924.23467.A3"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24335"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.02.011"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011163432007"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200522675"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-12929"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(91)90089-Z"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2522"},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.4049\/jimmunol.158.11.5418","article-title":"N\u2010acetylcysteine and alpha\u2010tocopherol reverse the inflammatory response in activated rat Kupffer cells","volume":"158","author":"Fox ES","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.10.056"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21638"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9741-4"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.10.083"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1235"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M103241200"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2009.02006.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2009.02006.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T18:40:41Z","timestamp":1697136041000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2009.02006.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,2]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1478-3231.2009.02006.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2009.02006.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,2]]}}}